Related references
Note: Only part of the references are listed.An Overview of the Adaptive Designs Accelerating Promising Trials Into Treatments (ADAPT-IT) Project
William J. Meurer et al.
ANNALS OF EMERGENCY MEDICINE (2012)
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
Laura J. Esserman et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials
Donald A. Berry et al.
CLINICAL CANCER RESEARCH (2012)
Worth Adapting? Revisiting the Usefulness of Outcome-Adaptive Randomization
J. Jack Lee et al.
CLINICAL CANCER RESEARCH (2012)
The impact of enrollment in clinical trials on survival of patients with glioblastoma
Tal Shahar et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2012)
Bayesian Adaptive Randomized Trial Design for Patients With Recurrent Glioblastoma
Lorenzo Trippa et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657
Laura J. Esserman et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wolfgang Wick et al.
LANCET ONCOLOGY (2012)
Phase 2 trial design in neuro-oncology revisited: a report from the RANO group
Evanthia Galanis et al.
LANCET ONCOLOGY (2012)
Adaptive clinical trials in oncology
Donald A. Berry
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival
Leland S. Hu et al.
NEURO-ONCOLOGY (2012)
Role of isocitrate dehydrogenase in glioma
Brian M. Alexander et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2011)
Adaptive Clinical Trials: The Promise and the Caution
Donald A. Berry
JOURNAL OF CLINICAL ONCOLOGY (2011)
Incorporation of Biomarker Assessment in Novel Clinical Trial Designs: Personalizing Brain Tumor Treatments
Evanthia Galanis et al.
CURRENT ONCOLOGY REPORTS (2011)
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Edward S. Kim et al.
CANCER DISCOVERY (2011)
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2010)
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G. W. Verhaak et al.
CANCER CELL (2010)
Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United States
Stuart A. Grossman et al.
CLINICAL CANCER RESEARCH (2010)
The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee
Lesley Seymour et al.
CLINICAL CANCER RESEARCH (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide
Mei-Yin C. Polley et al.
NEURO-ONCOLOGY (2010)
A multigene predictor of outcome in glioblastoma
Howard Colman et al.
NEURO-ONCOLOGY (2010)
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
A. D. Barker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients
Amy B. Heimberger et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
Kathleen R. Lamborn et al.
NEURO-ONCOLOGY (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography:: A pilot study
Wei Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
Karla V. Ballman et al.
NEURO-ONCOLOGY (2007)
Adaptive designs in clinical drug development - An Executive Summary of the PhRMA Working Group
Paul Gallo et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2006)
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
HS Phillips et al.
CANCER CELL (2006)
Bayesian clinical trials
DA Berry
NATURE REVIEWS DRUG DISCOVERY (2006)
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma
DA Hamstra et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens
MI Zia et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Bayesian statistics and the efficiency and ethics of clinical trials
DA Berry
STATISTICAL SCIENCE (2004)